SCHEMBL8532254

SCHEMBL8532254

CCCc1cc(C=C2SCN(C)C2=O)cc(CCC)c1O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
NAT1 P18440 4/20 0.36
PTGS1 P23219 2/20 0.34
PTGS2 P35354 2/20 0.34
ALOX5 P09917 1/20 0.34
COMT P21964 1/20 0.33
S1PR1 P21453 2/20 0.32
AURKA O14965 1/20 0.32
SIRT1 Q96EB6 1/20 0.32
EGFR P00533 1/20 0.32
ALDH1A1 P00352 2/20 0.32
GAA P10253 2/20 0.32
MEN1 O00255 2/20 0.32
POLB P06746 2/20 0.32
KMT2A Q03164 2/20 0.32
NPC1 O15118 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8532250 1.00 CYP1A2 (0.40) CYP1A2CYP3A4CYP2C9NAT1PTGS1
SCHEMBL8957287 0.91 CYP1A2 (0.50) CYP1A2CYP3A4CYP2C9NAT1PTGS1
SCHEMBL8933407 0.90 PTGS2 (0.44) CYP1A2CYP2C9PTGS1PTGS2ALOX5
SCHEMBL8895054 0.90 PTGS2 (0.44) CYP1A2CYP2C9PTGS1PTGS2ALOX5
SCHEMBL8533657 0.83 GAA (0.39) CYP1A2CYP3A4CYP2C9NAT1PTGS1
SCHEMBL8533654 0.83 GAA (0.39) CYP1A2CYP3A4CYP2C9NAT1PTGS1
SCHEMBL8532121 0.82 CYP1A2 (0.35) CYP1A2CYP3A4CYP2C9NAT1PTGS1
SCHEMBL8532119 0.82 CYP1A2 (0.35) CYP1A2CYP3A4CYP2C9NAT1PTGS1
SCHEMBL8537136 0.79 MEN1 (0.50) CYP1A2CYP3A4CYP2C9NAT1PTGS1
SCHEMBL8537140 0.79 MEN1 (0.50) CYP1A2CYP3A4CYP2C9NAT1PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0434394-B1 Compounds for treating inflammatory bowel disease LILLY CO ELI (US) 1998-08-05 EP disclosed
US-5731336-A USING ARYL-SUBSTITUTED RHODAMINES ELI LILLY AND COMPANY (US) 1998-03-24 US disclosed
US-5691367-A ANTIINFLAMMATORY AGENTS OR ANTIARTHRITIC AGENTS ELI LILLY AND COMPANY (US) 1997-11-25 US disclosed
WO-1996022772-A1 METHOD FOR TREATING MULTIPLE SCLEROSIS ELI LILLY AND COMPANY (US) 1996-08-01 WO disclosed
EP-0722729-A2 Aryl-substituted rhodanines for treating multiple sclerosis ELI LILLY AND COMPANY (US) 1996-07-24 EP disclosed
EP-0391644-B1 Aryl-substituted rhodanine derivatives LILLY CO ELI (US) 1996-06-19 EP disclosed
EP-0691129-A2 Thiazolidone and pyrrolidinone compounds for inhibiting bone loss ELI LILLY AND COMPANY (US) 1996-01-10 EP disclosed
US-5387690-A Method of treating inflammatory bowel disease ELI LILLY AND COMPANY (US) 1995-02-07 US disclosed
US-5356917-A Antiischemic, antiinflammatory, antiarthritic agents, treat-ment of dystrophic mammals ELI LILLY AND COMPANY (US) 1994-10-18 US disclosed
US-5216002-A Using benzyl substituted rhodanine derivatives as pure enantiomeric form ELI LILLY AND COMPANY (US) 1993-06-01 US disclosed
US-5158966-A Aryl-substituted rhodanine derivatives THE UNIVERSITY OF COLORADO FOUNDATION, INC. (US) 1992-10-27 US disclosed
EP-0500337-A1 Composition containing aryl-substituted rhodanine derivatives for the treatment of type I diabetes UNIVERSITY OF COLORADO FOUNDATION, INC. (US) 1992-08-26 EP disclosed
EP-0434394-A2 Compounds for treating inflammatory bowel disease ELI LILLY AND COMPANY (US) 1991-06-26 EP disclosed
EP-0391644-A2 Aryl-substituted rhodanine derivatives ELI LILLY AND COMPANY (US) 1990-10-10 EP disclosed